Mesenchymal stem cells elicits anti-pd1 immunotherapy by targeted delivery of cx3cl1

HIGHLIGHTS

• who: . and colleagues from the University Health Network (UHN), Canada have published the paper: Mesenchymal stem cells elicits Anti-PD1 immunotherapy by targeted delivery of CX3CL1, in the Journal: (JOURNAL)
• what: The authors speculate that CX3CL1 hypersecretion by MSC may be the main reason for the recruitment and engineering of CX3CR1high macrophages. The authors focus on the CX3CR1high macrophage subset, which showed significant changes in CRC, whose function in the TME also remains undefined.
• how: As a control PBS liposomes were used in the experiments. To investigate whether MSC could regulate CRC growth . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.